Completed

Assessment of Telangiectasias Improvement and Quality of Life in Breast Cancer Patients Treated with Pulsed Dye Laser

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to observe the improvement in quality of life in breast cancer survivors with radiation-induced telangiectasias, who are undergoing treatment with pulsed dye laser.

What is being collected

Behavioral Data

Collected from today forward - Prospective
Behavioral
Who is being recruted

Breast Diseases+6

+ Cardiovascular Diseases

+ Neoplasms

Over 18 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: February 2013
See protocol details

Summary

Principal SponsorMemorial Sloan Kettering Cancer Center
Last updated: February 7, 2018
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2013

Actual date on which the first participant was enrolled.

This study focuses on breast cancer survivors who have telangiectasias, which are small dilated blood vessels, on their radiated breast skin. The goal is to understand how the appearance of these telangiectasias, when improved by pulsed dye laser treatment, impacts the overall well-being of the patients. The study is important as it aims to enhance our understanding of how patients feel about the long-term effects of radiation on their skin, potentially leading to improved care and quality of life for breast cancer survivors. Patients participating in this study will undergo a series of treatments with a pulsed dye laser. This laser targets red blood vessels and delivers heat, causing the telangiectasias to shrink and become less noticeable. It has been safely used to treat telangiectasias on the skin of patients who received radiation for breast cancer. Throughout the study, patients will be asked to complete a questionnaire about their feelings towards the telangiectasias, their radiated skin, and how it affects their daily lives. The questionnaire will be given at every visit. The improvement in the appearance of the patients' radiated skin will also be compared to their responses to the questionnaire. The primary outcome of the study is to evaluate the quality of life in breast cancer survivors with chronic radiation-induced telangiectasias who are undergoing pulsed dye laser treatment, using two pre-existing validated scales, the Skindex-16 and BREAST-Q.

Principal SponsorMemorial Sloan Kettering Cancer Center
Last updated: February 7, 2018
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

22 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Breast DiseasesCardiovascular DiseasesNeoplasmsNeoplasms by SiteSkin DiseasesVascular DiseasesSkin and Connective Tissue DiseasesBreast NeoplasmsTelangiectasis

Criteria

3 inclusion criteria required to participate
Locally advanced breast cancer patients treated with surgery and adjuvant radiation

Patients 18 years or older

Telangiectasias in the radiation field of the treated breast

7 exclusion criteria prevent from participating
Breast/s reconstructed with implant in the area of previous radiation

Current oral steroid use or receiving daily therapeutic anticoagulation (e.g. Coumadin, Lovenox)

Fitzpatrick skin types V, VI

Non English speaking

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Memorial Sloan Kettering Cancer Center

New York, United StatesOpen Memorial Sloan Kettering Cancer Center in Google Maps
CompletedOne Study Center